Glimepiride (GMD) is a third-generation sulfonylurea derivative and one of the top three mostprescribed oral antidiabetic drugs. The need for a depot formulation exists, and a safe and effective antidiabetic therapy is the goal of this study. The aims were to design a depot in situ gel (ISG) formulation and investigate the main factors that control the initial burst and sustain the GMD effect using the Box-Behnken design. The studied factors were polymer percent (X 1 ), plasticizer percent (X 2 ) and benzyl benzoate percent in N-methyl-2-pyrrolidone (X 3 ). The results revealed that X 2 is the only factor that showed significant effects on all investigated responses. Scanning electron microscopy images showed that an increase in PEG % improved the smoothness and reduced the porosity of the ISG formulation surface. The GMD plasma levels in diabetic rats revealed no significant difference (p < 0.05) between the maximum GMD plasma concentrations of the optimized GMD-ISG formula (10 mg/ kg) and oral marketed GMD tablets (1 mg/kg). This result ensures that the optimized formula does not exceed the maximum safe plasma concentration. In addition, the optimized GMD-ISG formulation showed a depot effect that lasted for 14 days post-injection. This approach to controlling GMD release using an in situ forming system could be useful for improving patient compliance and diabetes treatment effectiveness.
dosing. ISG formulations rely on a solution of the polymer poly (d, l-lactide-co-glycolide) (PLGA) dissolved in a biocompatible and water-miscible or partially miscible solvent. The main challenge in ISG formulation design is the initially elevated amount of the drug released during the sol/gel transformation process of the polymer in the ISG formulation after injection 10 . The initial burst effect can result in exceeding the minimum toxic plasma concentration of the administered drug because of the increased amount of drug load (10-20 times the regular daily dose) included in the formula to cover the long period of release. The strategies used to reduce the initial burst effect include the incorporation of plasticizers such as polyethylene glycol (PEG) and the use of a hydrophobic solvent [11] [12] [13] . As such, a convenient depot of safe and effective antidiabetic therapy is the goal of this study. The Box-Behnken experimental design is used to investigate the factors that affect the performance of the GMD-ISG formula in the management of insulin non-dependent type II diabetes. Different formulations were prepared per the Box-Behnken experimental design. The studied factors were PLGA % (X 1 ), PEG % (X 2 ), and benzyl benzoate (BB) % in an N-methyl-2-pyrrolidone (NMP) solvent (X 3 ). Characterization of the prepared formulations was conducted to achieve the best performing formula. In addition, the in vivo pharmacokinetic parameters and hypoglycaemic activities were investigated in an animal model. This approach to controlling the release of GMD using in situ based biodegradable polymers could be useful for improving patient compliance and diabetes treatment effectiveness.
Results and Discussion
The major obstacle in the design of ISG formulations is the high initial burst of the drug after administration 6, [13] [14] [15] [16] . Accordingly, the goal was to sustain the release of GMD from the ISG formulation by controlling its initial burst from the designed formula. To attain this goal, the Box-Behnken design was applied for multiple response optimization of the data obtained from fifteen prepared formulations of GMD-ISG evaluated for drug release. The selected three factors, with three levels that primarily affect the reduction of GMD initial burst and sustain its release over a longer period, were considered in this study.
Surface morphology examination using SEM. SEM photographs ( Fig. 1) revealed that an increase in the percentage of PEG improved the smoothness and reduced the porosity of the prepared ISG formulation surfaces. These changes in the formulation surface characteristics lead to a reduction in the surface area exposed to the dissolution media, which subsequently reduces the initial burst effect of GMD release.
In vitro release of GMD from ISG formulations. The initial amount of GMD released after 2 and 24 h and the cumulative amount released after 28 days are presented in Table 1 . The effect of increasing the concentration of each studied factor on the release profile is presented in Fig. 2 . The results show that the maximum amount of GMD released after 28 days (3039.05 µg, 100%) was from the F11 formula, which contains low values of both X 1 andX 3 . Formula F14, which contains high levels of both X 1 and X 2 , released the minimum amount of GMD (1803.92 µg, 60.1%). However, F3, which contains high levels of both X 2 and X 3 , reduced the initial burst of GMD to 412.03 µg (13.7%) and 806.46 µg (26.9%) after 2 and 24 h, respectively. In addition, the results revealed that X 1 plays an important role in decreasing the initial burst of GMD from the prepared formulations. Formula F7, which contains a high level of PLGA, is an example of the previous finding.
Optimization of GMD-ISG using the response surface methodology. To reduce the rate of GMD release, the main factors that affect the release were investigated using the Box-Behnken experimental design. The mathematical design was applied to investigate, optimize, and explore the main interactions and quadratic effects of the selected factors on the initial burst after 2 and 24 h and the cumulative amount of GMD released after 28 days from the ISG formulations. These main factors were PLGA % (X 1 ), PEG % (X 2 ) and the percent of BB in NMP (X 3 ). These factors were selected based on previous and preliminary studies conducted in our laboratory.
Assessment of the quantitative effects of the factors. Statgraphics ® software was used to statistically analyse the 15 batch results from the Box-Behnken experimental design with two-way ANOVA followed by multiple regression analysis. Table 2 shows the estimated effects of the factors, the F-ratios, and the associated p-values on the three responses. A p-value of less than 0.05 is considered significant.
According to the Pareto chart in Fig. 3 and the results in Table 2 , the percentage of PEG (X 2 ) is the only factor that showed significant effects on the three investigated responses, (Fig. 3 ). It was found that PEG % (X 2 ) has a relatively larger coefficient in the regression equations, which endorses its significant effect on the studied responses because its bar extends beyond the reference line. As shown in Fig. 3 the percentage of PLGA (X 1 ) has an antagonistic effect on the initial burst after 2 h (Y 1 ) and the cumulative amount released after 28 days (Y 3 ). The percentage of BB in NMP (X 3 ) displayed an antagonistic effect on the initial burst after 2 h (Y 1 ) and the amount released after 24 h (Y 2 ), whereas the quadratic term of the factor X 1 had a synergistic effect on the same responses. It was noted from the 3D response surface plot (Fig. 4 ) that an inverse relationship exists between X 1 and Y 3 , which indicates that the PLGA % (X 1 ) determines the cumulative amount of GMD released after 28 days (Y 3 ). At the same concentrations of both X 2 and X 3 , as the concentration of PLGA increased from 20 to 30%, Y 3 decreased from 2972.38 in F6 to 2517.45 µg in F7, from 2928.37 in F12 to 2181.8 µg in F10, and from 3039.05 in F11 to 2570.78 µg in F4. This observation can be attributed to the presence of PLGA at higher concentrations, which hastens the solidification of the formulation and subsequently reduces the leaching of GMD to the surrounding phase 6, 15, 17, 18 . To a certain extent, the same finding was attained in the initial burst after 2 h in the previous formulations. However, incorporation of PEG in the ISG formulation significantly affects all of the release parameters investigated in this study. The Pareto charts (Fig. 3 ) and 3D response surface plots (Fig. 4) demonstrate that an inverse relationship exists between the PEG % (X 2 ) and the release of GMD from ISG at all time points of the study. When the PEG concentration increased from 0 to 10% in the formulation with constant levels of X 1 and X 3 , the initial burst of GMD after 2 h (Y 1 ) decreased from 1020.24 to 823.58 µg in F5 and F2, respectively; from 890.82 to 647.48 µg in F12 and F9, respectively; and from 745.37 to 578.7 µg in F10 and F14, respectively. Additionally, the amount of GMD released after 24 h (Y 2 ) decreased as the PEG concentration in the formulations increased from 0 ) from 10% to 0% at the same level of X 1 and X 3 . This result could be attributed to the decrease in the transition temperature of PLGA, which leads to rapid congealing of the formulation as a result of the increase in the percentage of PEG in the formulation 12 . In addition, SEM photographs ( Fig. 1) revealed that an increase in the percentage of PEG improved the smoothness and reduced the porosity of the ISG formulation surface, which decreased the surface area exposed to the dissolution media and subsequently reduced the release of GMD 12, 19 . Finally, the release behaviour of GMD from the ISG formulations was affected by the hydrophobicity of the solvent from which they were prepared, i.e., the percentage of BB in NMP (X 3 ). It was noted that X 3 significantly and decreased to 412.03 µg in F3 after 2 h. In addition, the amount of GMD released was 1114.11 µg in F2 and decreased to 806.46 µg in F3 after 2 h. This finding can be attributed to the effect of BB in decreasing the solvent affinity of PLGA solutions for aqueous fluids to slow the rate of phase inversion and yield a more uniform prolonged release 15, [20] [21] [22] .
Prediction of the optimized GMD-ISG formulation. After analysis of the experimental factors, an
optimum combination of these factors was achieved. The results of the analysis suggested an optimized ISG formulation containing 25.4% PLGA, 3.4% PEG, and 20% BB in NMP. The optimized formula was prepared and evaluated to confirm the validity of the observed optimal parameters and the predicted responses. The observed values for Y 1, Y 2 , and Y 3 were 476.42 µg (15.9%), 877.64 µg (29.2%) and 3105.85 µg (103.5%), respectively, and the predicted values were 454.102, 857.893 and 2952.38 µg, respectively. As a result, it can be concluded that the optimized combination of the independent factors confirmed the desired release behaviour of GMD from the ISG formulations. This outcome also verified the reliability of the optimization procedure in the development of a GMD-ISG formulation characterized by a sustained release pattern.
In vivo study. Assessment of the GMD-ISG hypoglycaemic efficacy.
The hypoglycaemic efficacies of the optimized GMD-ISG formula and marketed tablets showed a reduction in plasma glucose levels compared with the control group after 1, 2 and 4 h of dose administration (Fig. 5) . The optimized GMD-ISG formula extended the reduction in glucose levels compared with the control group for up to 168 h after administration. These results showed the effectiveness of the depot action of the optimized GMD-ISG formulation in reducing glucose levels for a longer period than the marketed GMD tablets.
Quantification of the GMD plasma levels.
The initial burst is a major concern in the design and development of depot ISG formulations. The goal of this investigation was to estimate the GMD plasma levels of the optimized GMD-ISG formula compared with those of oral administration of marketed GMD tablets to assess the initial burst effect and the C max levels of GMD. The injected optimized depot GMD dose was 10 times the administered oral dose. The results in Fig. 6 revealed no significant difference (p < 0.05) in C max values between the optimized ISG and the marketed oral dose formulations. The optimized GMD-ISG formula showed a C max of 520.168 ± 168.642 ng/mL, whereas the marketed oral tablets showed a C max of 355.213 ± 144.998 ng/mL. Additionally, the optimized GMD-ISG formula and marketed oral tablets showed t max values of 4 h and 2 h, respectively. These results revealed that the initial burst of the optimized depot GMD-ISG formula did not significantly exceed the C max of the marketed oral (low-dose) tablets. The inclusion of the optimum levels of factors (X 1 , X 2 , and X 3 parameters) from the experimental design in the formulation reduced the initial amount of GMD released after injection of the GMD-ISG formula. Accordingly, these results indicated the possibility of safe administration for the optimized depot GMD-ISG dose.
Achievement of long-lasting GMD therapy could have a positive impact on the antidiabetic therapy 23 . Depot treatment could improve patient compliance and reduce the individual variation in bioavailability that could result from GMD oral treatment. In addition, depot therapy could improve the correlation between the administered GMD dose and its plasma concentration compared with oral therapy. Furthermore, the control of plasma glucose levels and reduction of side effects are better achieved when adjusting the dose frequency of the depot ISG formula, and the prescriber can be confident that the patient receives the required dose. However, findings should be examined in further pre/clinical studies that are necessary prior to the use of the GMD-ISG formula as Table 2 . Estimated effects of factors, F-ratios, and associated P-values for all responses (Y 1 , Y 2 , and Y 3 ). Note: *Significant effect of factors on individual dependent variables. Abbreviations: X 1 , PLGA %; X 2 , PEG %; X 3 , BB % in NMP; Y 1 , initial amount of GMD released after 2 hours (μg); Y 2 , amount of GMD released after 24 hours (μg); Y 3 , cumulative amount of GMD released after 28 days (μg); X 1 2 , X 2 2 , and X 3 2 are the quadratic terms for the factors, and X 1 X 2 , X 1 X 3 , and X 2 X 3 are the interaction terms between the factors. a valuable alternative to oral antidiabetic therapy for patient convenience and compliance with minimum or no risks of inadvertent hypoglycaemia.
Materials and Methods
Materials. GMD was a kind gift from Spimaco Addwaeih, Riyadh, KSA. Poly(DL-lactide-co-glycolide) (PLGA, 50:50, inherent viscosity range 0.55-0.75 dL/g) was sourced from LACTEL Absorbable polymers, Box-Behnken experimental design. Three factors were selected per the obtained preliminary data. These factors were PLGA % (X 1 ), PEG % (X 2 ), and BB % in NMP (X 3 ). Their effects on the initial amount of GMD released after 2 h (Y 1 ), the amount of GMD released after 24 h (Y 2 ) and the cumulative amount of GMD released after 28 days (Y 3 ) were investigated. The development of different GMD-ISG formulations per various levels of independent variables (Table 3) was conducted using the Box-Behnken experimental design (Statgraphics Centurion XV version 15.2.05 software, StatPoint Technologies Inc., Warrenton, VA, USA). The experimental design was chosen to minimize all of the investigated dependent variables. The polynomial equations generated from the obtained results were used to obtain the relationships between the investigated independent variables and the dependent variables.
Formulation of GMD loaded in situ gel formulations. The specified amount of polymer PLGA was dissolved in 2 mL of the solvent system per the Box-Behnken experimental design. GMD (6 mg) was added to the polymeric solution and mixed by vortexing until complete dissolution. All prepared formulations were injected through a 21-gauge needle.
Surface morphology examination using scanning electron microscopy. The surface characteristics of the optimized GMD formulations were investigated after gelation and lyophilization using scanning electron microscopy (SEM). For the gelation process, each formulation was injected separately into a buffer solution of pH 7.4 at 37 °C, held for 24 h, and finally collected and lyophilized. The lyophilized formulation was mounted on metal stubs with conductive silver paint, sputtered with gold and subjected to characterization using SEM (Philips XL30; FEI, Hillsboro, OR, USA). The resulting photographs were used to investigate the effect of PEG concentrations (0%, 5% and 10% PEG) on the surface morphology of the selected GMD-ISG systems.
In vitro release of GMD biodegradable ISG formulations. In vitro GMD release from the ISG formulations was investigated via the modified dialysis method, as described previously 6 . In brief, a GMD formula equivalent to 3 mg was injected into a dialysis tube (Sigma-Aldrich, St. Louis, MO. USA, molecular weight cut-off of 12,000 Da) containing 10 mL of phosphate buffered solution at pH 7.2. After sealing, the tubes were inserted into vessels of the USP II dissolution apparatus containing 250 mL of buffer at pH 7.2 and 37 °C with agitation at 100 rpm. Aliquots of 5 mL each were assayed for GMD content using HPLC, as described in the in Figure 5 . Hypoglycaemic activity of the administered GMD from an optimized GMD-ISG formula (dose 10 mg/kg, IM injection) and marketed oral tablets (dose 1 mg/kg, oral). Diabetes was induced by intraperitoneal injection with 50 mg/kg streptozotocin two weeks prior to the study 8 .
Fasting blood glucose levels were assessed using Accu-Chek ® Go (Roche, Mannheim, Germany). Rats with moderate diabetes, i.e., fasting blood glucose levels in the range of 250-350 mg/dl, were selected for the study. The animals were divided into 3 groups. The first group was injected intramuscularly with 250 μL of plain ISG formula representing the negative control. Group 2 was given commercial GMD tablets orally at 1 mg/kg body weight 24 . Group 3 was injected intramuscularly with 250 μL of the optimized GMD-ISG formula (equivalent to 10 mg GMD).
Quantification of the GMD plasma levels. Pharmacokinetic calculations based on plasma GMD concentrations were performed via non-compartmental analysis using groups 2 and 3, as described in the previous section. The maximum plasma concentration (C max ) and time point of maximum plasma concentration (t max ) were calculated using Kinetica software v4.2 (Thermo Scientific Corporation, Philadelphia, PA, USA). Blood samples (0.25 mL) were withdrawn at 0 (pre-dose), 1, 2, 4, 8, 12, 24, 48, 96, 168 and 336 hours. GMD concentrations were analysed using the HPLC method. The HPLC system consisted of an Agilent 1200 system, a solvent delivery module, a quaternary pump, an autosampler, a diode-array detector (DAD), and a column compartment (Agilent Technologies, Santa Clara, CA, USA). The separation was performed on an Agilent Zorbax Eclipse Plus C18 column, 3.5 µm, 4.6 × 100 mm and maintained at 35 °C. The analytes were isocratically eluted using a mobile system composed of acetonitrile:0.1% formic acid in water (60:40, v/v) and pumped at a flow rate of 1 mL/min with detection at λ = 230 nm. Plasma GMD concentrations were analysed after liquid-liquid extraction with methanol using the Sujatha et al. method 25 .
Data availability. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
Conclusions
The results in this work indicated the successful application of the experimental design to develop a GMD-ISG formulation for long-lasting GMD release. To reduce the rate of GMD release, the main factors that affect the release were investigated via the Box-Behnken experimental design. The results revealed that PEG is the only factor investigated that showed a significant effect on all of the investigated responses. The in vivo data from diabetic rats displayed the ability of the optimized formula to reduce plasma glucose levels for extended periods compared with orally administered marketed tablets. The optimized formula dose (10 mg/kg) exhibited no significant difference in the C max of GMD compared with that of the marketed oral tablets dose (1 mg/kg). The achievement of a long-lasting GMD-ISG formula is expected to benefit patient compliance and reduce inadvertent hypoglycaemia. Table 3 . Independent and dependent variables in the Box-Behnken experimental design. Abbreviations: PLGA, poly (D, L-lactide-co-glycolide); PEG, polyethylene glycol; BB, benzyl benzoate; NMP, N-methyl-2-pyrrolidone.
Independent variables Levels

